Clinical Trial

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to confirm the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of ravulizumab in the treatment of Chinese adults with anti-aquaporin-4 (AQP4) antibody (Ab) + neuromyelitis optica spectrum disorder (NMOSD).
Protocol Amendment History 2 changes
notable Enrollment increased: 19 -> 21 participants 2026-06-19
notable Trial sites expanded: 1 -> 5 locations 2026-06-19
Trial Details
NCT Number NCT07557420
Lead Sponsor Alexion Pharmaceuticals, Inc.
Conditions NMOSD, Neuromyelitis Optica Spectrum Disorder
Enrollment 21 participants
Start Date 2026-08-31
Primary Completion 2028-10-31 (estimated)
Study Completion 2028-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-18